COVID-19 Ontario Prescription Drug Utilization Tool
To help characterize the impact of COVID-19 on drug prescribing, this newly released tool provides public access to data on drug utilization in Ontario during the COVID-19 pandemic
Geographic variation in the provision of naloxone by pharmacies in Ontario
This study investigates regional variation in the distribution of naloxone through the ONPP and identifies individual- and public health unit-level determinants of variation.
Spending on hepatitis C antivirals in the United States and Canada, 2014 to 2018
This case-study explores differences in drug spending between Canada and the US to compare drug expenditures on hepatitis C virus medications.
This study describes the characteristics of high drug-cost beneficiaries (the top 5% of public drug program beneficiaries based on annual costs) in 9 provinces across Canada, to inform current planning around national drug strategies.
This study explores whether oxycodone and hydromorphone are differentially associated with suicide.
Current and prospective utilization of innovator biologics and biosimilars in Ontario
This report describes the current and prospective utilization patterns and expenditures of innovator biologics and biosimilars through the public drug program in Ontario, Canada.